Subscribe
shutterstock_393927661_marbury
marbury / Shutterstock.com
3 May 2019Big Pharma

NHS partners with drugmakers to eliminate hep C

The National Health Service (NHS), the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme (MSD) and AbbVie to help eliminate hepatitis C in England.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
NHS to save £300m in biosimilar adalimumab deals
29 November 2018   The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
Big Pharma
UK life sciences partnership to use AI in disease detection
5 December 2018   The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
Big Pharma
NHS to receive £250m for new AI lab
8 August 2019   The NHS will receive a £250 million investment to develop a new National AI Lab, which will use the technology to improve patient health, the UK government has announced.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Biotechnology
NHS to save £300m in biosimilar adalimumab deals
29 November 2018   The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
Big Pharma
UK life sciences partnership to use AI in disease detection
5 December 2018   The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
Big Pharma
NHS to receive £250m for new AI lab
8 August 2019   The NHS will receive a £250 million investment to develop a new National AI Lab, which will use the technology to improve patient health, the UK government has announced.

More on this story

Biotechnology
NHS to save £300m in biosimilar adalimumab deals
29 November 2018   The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
Big Pharma
UK life sciences partnership to use AI in disease detection
5 December 2018   The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
Big Pharma
NHS to receive £250m for new AI lab
8 August 2019   The NHS will receive a £250 million investment to develop a new National AI Lab, which will use the technology to improve patient health, the UK government has announced.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent